参考文献

1 Feinberg WM, Blackshear JL, Laupacis A, et al.

Prevalence, age, distribution and gender of patients

with atrial fibrillation:analysis and implications[J].

Arch Intern Med, 1995, 155:469-473.

2 Go AS, Hylek EM, Phillips KA, et a1. Prevalence

of diagnosed atrial fibrillation in adults:national

implications for rhythm management and stroke

prevention:the Anticoagulation and Risk Factors in

Atrial Fibrillation (ATRIA) Study[J]. JAMA, 2001,

295:2370-2375.

3 Har t RG, Halper in JL. At r ial f ibr illation and

thromboembolism:a decade of progross in stroke

prevention[J]. Ann Intem Med, 1999, 131:688-695.

4 Winter Y, Wolfram C, Schaeg M, et al. Evaluation of

costs and outcome in cardioembolic stroke or TIA[J].

J Neurol, 2009, 256:954-963.

5 Schneck M, Lei X. Cardioembolic stroke[J/OL]. eMed

Neurol, 2008.

6 Bruggenjurgen B, Rossnagel K, Roll S, et al. The

impact of atrial fibrillation on the cost of stroke:The

berlin acute stroke study[J]. Value Health, 2007,

10:137-143. ht t p: //eme d ic i ne.me d s c ap e.com/

article/1160370-overview.

7 Jorgensen HS, Nakayama H, Reith J, et a1. Acute

stroke with atrial fibrillation. The Copenhagen Stroke

Study[J]. Stroke, 1996, 27:1765-1769.

8 Marini C, De Santis F, Sacco S, et a1. Contribution

of atrial fibrillation to incidence and outcome of

ischemic stroke:results from a population-based

study[J]. Stroke, 2005, 36:1115-1119.

9 Steger C, Pratter A, Martinek-Bregel M, et a1. Stroke

patients with atrial fibrillation have a worse prognosis

than patients without:data from the Austrian Stroke

registry[J]. Eur Heart J, 2004, 25:1734-1740.

10 Wann LS, Curtis AB, January CT, et al. 2011 ACCF/

AHA/HRS focused update on the management of

patients with atrial fibrillation (updating the 2006

guideline):A report of the American College of

Cardiology Foundation/American Heart Association

task force on practice guidelines[J]. Circulation, 2011,

123:104-123.

11 Connolly S, Pogue J, Hart RP, et al. Clopidogrel

plus aspirin versus oral anticoagulation for atrial

fibrillation in the atrial fibrillation clopidogrel trial

with irbesartan for prevention of vascular events

(active w):A randomised controlled trial[J]. Lancet,

2006, 367:1903-1912.

12 Nieuwlaat R, Capucci A, Lip GY, et al. Euro Heart

Survey Investigators. Antithrombotic treatment in

real-life atrial fibrillation patients:a report from the

Euro Heart Survey on Atrial Fibrillation[J]. Eur Heart

J, 2006, 27:3018-3026.

13 Reynolds MW, Fahrbach K, Hauch O, et al. Warfarin

anticoagulation and outcomes in patients with atrial

fibrillation:A systematic review and meta analysis[J].

Chest, 2004, 126:1938-1945.

14 [No authors listed]. Risk factors for stroke and

efficacy of antithrombotic therapy in atrial fibrillation.

Analysis of pooled data from f ive randomized

controlled trials[J]. Arch Intern Med, 1994, 154:1449-

1457.

15 Stroke Prevention in Atrial Fibrillation Investigators.

Risk factors for thromboembolism during aspirin

therapy in patients with atrial fibrillation:The Stroke

Prevention in Atrial Fibrillation Study[J]. J Stroke

Cerebrovasc Dis, 1995, 5:147-157.

16 van Latum JC, Koudstaal PJ, Venables GS, et al.

Algra A for the European Atrial Fibrillation Trial

(EAFT) Study Group. Predictors of major vascular

events in patients with a transient ischemic attack

or minor ischemic stroke with nonrheumatic atrial

fibrillation[J]. Stroke, 1995, 16:801-806.

17 Wang TJ, Massaro JM, Levy D, et al. A risk score

for predicting stroke or death in individuals with

new-onset atrial fibrillation in the community:The

Framingham heart study[J]. JAMA, 2003, 290:1049-

1056.

18 National Collaborating Centre for Chronic Conditions.

Atrial Fibrillation:National Clinical Guideline for

Managementin Primary and Secondary Care[M].

London:Royal College of Physicians, 2006.

19 Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/

ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary:A report of

the American College of Cardiology/American Heart

Association task force on practice guidelines and

the European Society of Cardiology committee for

practice guidelines (writing committee to revise the

2001 guidelines for the management of patients with

atrial fibrillation)[J]. Eur Heart J, 2006, 27:1979-2030.

20 Singer DE, Albers GW, Dalen JE, et al; American

College of Chest Physicians. Antithrombotic therapy

in atrial fibrillation:American College of Chest

Physicians evidence-basedclinical practice guidelines

(8th edition) [J]. Chest, 2008, 133:546S-592S.

21 Reitbrock S, Heeley E, Plumb J, et al. Chronic atrial

fibrillation:incidence, prevalence and prediction

of st roke using the Congest ive hea r t failu re,

Hypertension, Age>75, Diabetes mellitus, and prior

Stroke or transient ischemic attack (CHADS2) risk

stratification scheme[J]. Am Heart J, 2008, 156:57-64.

22 Gage BF, Waterman AD, Shannon W, et al. Validation

of clinical classification schemes for predicting

stroke:Results from the national registry of atrial

fibrillation[J]. JAMA, 2001, 285:2864-2870.

23 Lip GY, Nieuwlaat R, Pisters R, et al. Refining

clinical risk stratification for predicting stroke and

thromboembolism in atrial fibrillation using a novel

risk factor-based approach:The Euro Heart Survey on

atrial fibrillation[J]. Chest, 2010, 137:263-272.

24 Keogh C, Wallace E, Dillon C, et al. Validation of the

CHADS2 clinical prediction rule to predict ischaemic

stroke. A systematic review and meta-analysis[J].

Thromb Haemost, 2011, 106:528-538.

25 Olesen JB, Lip GY, Hansen ML, et al. Validation

of risk stratification schemes for predicting stroke

and th romboembolism in pat ient s with at r ial

fibrillation:Nationwide cohort study[J]. BMJ, 2011,

342:d124.

26 Lip GY, Frison L, Halperin JL, et al. Identifying

patients at high risk for stroke despite anticoagulation:

A comparison of contemporary stroke risk

stratification schemes in an anticoagulated atrial

fibrillation cohort[J]. Stroke, 2010, 41:2731-2738.

27 Lip GY, Lim HS. Atrial f ibrillation and stroke

prevention[J]. Lancet Neurol, 2007, 6:981-993.

28 Baruch L, Gage BF, Horrow J, et al. Can patients at

elevated risk of stroke treated with anticoagulants be

further risk stratified[J]. Stroke, 2007, 38:2459-2463.

29 Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus

aspirin for stroke prevention in an elderly community

population with atrial fibrillation (the Birmingham

Atrial Fibrillation Treatment of the Aged Study,

BAFTA):A randomised controlled trial[J]. Lancet,2007, 370:493-503.

30 Fang MC, Go AS, Chang Y, et al. A new risk scheme

to predict warfarin-associated hemor rhage:The

ATRIA (Anticoagulation and Risk Factors in Atrial

Fibrillation) study[J]. J Am Coll Cardiol, 2011, 58:395-

401.

31 Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk

of bleeding with 2 doses of dabigatran compared with

warfarin in older and younger patients with atrial

fibrillation. An analysis of the Randomized Evaluation

of Long-Term Anticoagulant Therapy (RE-LY)

Trial[J]. Circulation, 2011, 123:2363-2372.

32 ROCKET AF Study Investigators. Rivaroxabanonce

daily, oral, direct factor Xa inhibition compared

with vitamin K antagonism for prevention of stroke

and embolism trial in atrial fibrillation:Rationale

and design of the ROCKET AF study[J]. Am Heart J,

2010, 159:340-347, e341.

33 Hankey GJ, Patel MR, Stevens SR, et al. Rivaroxaban

compared with warfarin in patients with atrial

fibrillation and previous stroke or transient ischaemic

attack:A subgroup analysis of ROCKET AF[J]. Lancet

Neurol, 2012, 11:315-322.

34 Stuart JC, John E, Campbell J, et al. Apixaban in

patients with atrial fibrillation[J]. N Engl J Med, 2011,

364:806-817.

35 Granger CB, Alexander JH, Mcmurray JJ, et al.

Apixaban versus warfarin in patients with atrial

fibrillation[J]. N Engl J Med, 2011, 365:981-992.

36 Beyth RJ, Qui m LM, Landefeld CS. Prospective

evaluation of an index for predicting the risk of major

bleeding in outpatients treated with warfarin[J]. Am J

Med, 1998, 105:91-99.

37 Kuijer PM, Hutten BA, Prins MH, et a1. Prediction of

the risk of bleeding during anticoagulant treatment for

venous thromboembolism[J]. Arch Intern Med, 1999,

159:457-460.

38 Shireman TI, Mahnken JD, Howard PA, et al.

Development of a contemporary bleeding risk model

for elderly warfarin recipients[J]. Chest, 2006,

130:1390-1396.

39 Gage BF, Yan Y, Milligan PE, et a1. Clinical

c l a s s i f i c a t i o n s c h e m e s f o r p r e d i c t i n g

hemorrhage:results from the National Registry of

Atrial Fibrillation (NRAF)[J]. Am Heart J, 2006,

151:713-719.

40 Pisters R, Lane DA, Nieuwlaat R, et al. A novel userfriendly

score (HAS-BLED) to assess 1-year risk of

major bleeding in patients with atrial fibrillation:The

Euro Heart Survey[J]. Chest, 2010, 138:1093-1100.

41 Romero-Ortuno R, O'Shea D. Aspirin versus warfarin in atrial fibrillation:Decision analysis may help

patients' choice[J]. Age Ageing, 2012, 41:250-254.

42 Fang MC, Go AS, Chang Y, et al. A new risk scheme

to predict warfarin-associated hemorrhage:The ATRIA

(Anticoagulation and Risk Factors in Atrial Fibrillation)

study[J]. J Am Coll Cardiol, 2011, 58:395-401.

43 Apostolakis S, Lane DA, Guo Y, et al. Performance of

the hemorrhages, atria, and HAS-BLED bleeding riskprediction

scores in patients with atrial fibrillation

u nde rgoi ng a nt icoag ul at ion:The AMADEUS

(evaluating the use of sr34006 compared to warfarin

or acenocoumarol in patients with atrial fibrillation)

study[J]. J Am Coll Cardiol, 2012, 60:861-867.

44 Lip GY. Stroke and bleeding risk assessment in atrial

fibrillation:When, how, and why?[J]. Eur Heart J,

2013, 34:1041-1049.

45 Lip GY, Lin HJ, Hsu HC, et al. Compa rat ive

assessment of the HAS-BLED score with other

published bleeding r isk scor ing schemes, for

int racranial haemor rhage r isk in a non-at r ial

fibrillation population:The Chin-Shan community

cohort study[J]. Int J Cardiol, 2013, 168:1832-1836.

46 Roldan V, Marin F, Fernandez H, et al. Predictive

va lue of t he HAS-BLED a nd a t r i a ble e d i ng

scores for the risk of serious bleeding in a "realworld"

population with atrial fibrillation receiving

anticoagulant therapy[J]. Chest, 2013, 143:179-184.

47 Camm AJ, Kirchhof P, Lip GY, et a1. Guidelines for

the management of atrial fibrillation:the task force for

the management of atrial fibrillation of the European

Society of Cardiology (ESC)[J]. Eur Heart J, 2010,

31:2369-2429.

48 Ca i r n s JA, Cormol ly S, MeMu r t r y S, e t a1.

Canadian Cardiovascular Society atrial fibrillation

guidelines 2010:prevention of stroke and systemic

thromboembolism in atrial fibrillation and flutter[J].

Can J Cardiol, 2011, 27:74-90.

49 Paciaroni M, Agnelli G, Micheli S, et al. Efficacy

and safety of anticoagulant treatment in acute

cardioembolic stroke:A meta-analysis of randomized

controlled trials[J]. Stroke, 2007, 38:423-430.

50 Taya AH, Tian M, Kelly KM, et al. Atrial fibrillation

detected by mobile cardiac outpatient telemetry

in cryptogenic TIA or stroke[J]. Neurology, 2008,

71:1696-1701.

51 D o u e n AG , P a g e a u N , Me d i c S . S e r i a l

electrocardiographic assessments signif icantly

improve detection of atrial fibrillation 2.6-fold in

patients with acute stroke[J]. Stroke, 2008, 39:480-

482.

52 Kamel H, Hegde M, Johnson DR, et al. Costeffectiveness

of outpatient cardiac monitoring to

detect atrial fibrillation after ischemic stroke[J].

Stroke, 2010, 41:1514-1520.

53 Stahrenberg R, Weber-Kruger M, Seegers J, et al.

Enhanced detection of paroxysmal atrial fibrillation

by early and prolonged continuous holter monitoring

in patients with cerebral ischemia presenting in sinus

rhythm[J]. Stroke, 2010, 41:2884-2888.

54 Cotter PE, Martin PJ, Ring L, et al. Incidence of atrial

fibrillation detected by implantable loop recorders in

unexplained stroke[J]. Neurology, 2013, 80:1546-1550.

55 Suissa L, Bertora D, Lachaud S, et al. Score for

the Targeting of Atrial Fibrillation (STAF):a new

approach to the detection of atrial fibrillation in the

secondary prevention of ischemic stroke[J]. Stroke,

2009, 40:2866-2868.

56 Suissa L, Mahagne MH, Lachaud S. Score for the

targeting of atrial f ibrillation:A new approach

to diagnosing paroxysmal atrial f ibrillation[J].

Cerebrovasc Dis, 2011, 31:442-447.

57 Horstmann S, Rizos T, Guntner J, et al. Does the

STAF score help detect paroxysmal atrial fibrillation

in acute stroke patients?[J]. Eur J Neurol, 2013, 20:147-

152.

58 Malik S, Hicks WJ, Schultz L, et al. Development of

a scoring system for atrial fibrillation in acute stroke

and transient ischemic attack patients:The LADS

scoring system[J]. J Neurol Sci, 2011, 301:27-30.

59 Suissa L, Lachaud S, Mahagne MH. Optimal timing

and duration of continuous electrocardiographic

monitoring for detecting atrial fibrillation in stroke

patients[J]. J Stroke Cerebrovasc Dis, 2013, 22:991-

995.

60 Ritter MA, Kochhauser S, Duning T, et al. Occult

atrial fibrillation in cryptogenic stroke:Detection by

7-day electrocardiogram versus implantable cardiac

monitors[J]. Stroke, 2013, 44:e135.

61 Hong HJ, Kim YD, Cha MJ, et al. Early neurological

outcomes according to CHADS2 score in stroke

patients with non-valvular atrial fibrillation[J]. Eur J

Neurol, 2012, 19:284-290.

62 Sato S, Yazawa Y, Itabashi R,et al. Pre-admission

CHADS2 score is related to severity and outcome of

stroke[J]. J Neurol Sci, 2011, 307:149-152.

63 Giralt-Steinhauer E, Cuadrado-Godia E, Ois A, et

al. CHA2DS2_VASc score and prognosis in ischemic

strokes with atrial fibrillation[J]. J Neurol, 2012,

259:745-751.

64 Ntaios G, Lip GY, Makaritsis K, et al. CHADS2,

CHA2DS2_VASc, and long-term stroke outcome in

patients without atrial fibrillation[J]. Neurology, 2013,80:1009-1017.

65 Saposnik G, Kapral MK, Liu Y, et al. iScore:A risk

score to predict death early after hospitalization for an

acute ischemic stroke[J]. Circulation, 2011, 123:739-

749.

66 Saposnik G, Raptis S, Kapral MK, et al. The iScore

predicts poor functional outcomes early af ter

hospitalization for an acute ischemic stroke[J]. Stroke,

2011, 42:3421-3428.

67 Saposnik G, Demchuk A, Tu JV, et al. The iScore

predicts efficacy and risk of bleeding in the national

institute of neurological disorders and stroke tissue

plasminogen activator stroke trial[J]. J Stroke

Cerebrovasc Dis, 2012, 22:876-882.

68 Saposnik G, Fang J, Kapral MK, et al. The iScore

predicts effectiveness of thrombolytic therapy for

acute ischemic stroke[J]. Stroke, 2012, 43:1315-1322.

69 O'Donnell MJ, Fang J, D'Uva C, et al. The PLAN

score:A bedside prediction rule for death and severe

disability following acute ischemic stroke[J]. Arch

Intern Med, 2012, 172:1548-1556.

70 Smith EE, Shobha N, Dai D, et al. Risk score for

in-hospital ischemic stroke mortality derived and

validated within the get with the guidelines-stroke

program[J]. Circulation, 2010, 122:1496-1504.

71 Ntaios G, Faouzi M, Ferrari J, et al. An integer-based

score to predict functional outcome in acute ischemic

stroke:The ASTRAL score[J]. Neurology, 2012,

78:1916-1922.

72 Muscari A, Puddu GM, Santoro N, et al. A simple

scoring system for outcome prediction of ischemic

stroke[J]. Acta Neurol Scand, 2011, 124:334-342.

73 Ovbiagele B, Liebeskind DS, Kim D, et al. Prognostic

value of Framingham cardiovascular risk score in

hospitalized stroke patients[J]. J Stroke Cerebrovasc

Dis, 2011, 20:222-226.

74 Huxley RR, Lopez FL, Folsom AR, et al. Absolute

and at t r ibut able r isks of at r ial f ibr illat ion in

relation to optimal and borderline risk factors:The

Atherosclerosis Risk In Communities (ARIC) study[J].

Circulation, 2011, 123:1501-1508.

75 Yusuf S, Healey JS, Pogue J, et al. Irbesartan in

patients with atrial fibrillation[J]. N Engl J Med, 2011,

364:928-938.